白蛋白结合型紫杉醇在妇科肿瘤中的研究进展  

Research Progress of Albumin-bound Paclitaxel in Gynecologic Oncology

作　　者：曾靖[1] 张蓉[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院肿瘤研究所妇瘤科,北京100021

出　　处：《国际妇产科学杂志》2014年第3期232-235,共4页Journal of International Obstetrics and Gynecology

摘　　要：白蛋白结合型紫杉醇是一种以白蛋白为溶剂的新型紫杉醇制剂,相对于传统紫杉醇制剂(溶剂为聚氧乙烯蓖麻油和无水乙醇),其抗肿瘤能力更强且血液毒性、严重过敏反应等毒副作用更小。近几年来,白蛋白结合型紫杉醇应用范围越来越广泛,其在妇科肿瘤中的临床研究也相继开展。分别为单药白蛋白结合型紫杉醇应用于铂类敏感及耐药型的复发性卵巢癌、腹膜癌和输卵管癌;白蛋白结合型紫杉醇联合贝伐单抗治疗铂类抵抗或铂类难治的复发性卵巢癌、腹膜癌和输卵管癌,结果显示白蛋白结合型紫杉醇疗效明显且不良反应可耐受。白蛋白结合型紫杉醇在复发或转移性中晚期宫颈癌中的Ⅱ期临床研究结果显示,白蛋白结合型紫杉醇是一种值得考虑且不良反应小的药物。总的来说,有关白蛋白结合型紫杉醇在妇科肿瘤中的临床研究相对较少,需进一步研究。Albumin-bound paclitaxel is a novel formulation of paclitaxel with albumin as its solvent. Compare to the conventional paclitaxel formulation （solvent is polyoxyethylene castor oil and ethanol）,its anti-tumor capability is more effective and hematologic toxicity ,severe allergic reaction and other side effects are less. In recent years ,albumin-bound paclitaxel are widely used on clinical studies of gynecologic oncology. There are three Phase Ⅱ clinical studies currently reported on ovarian cancer,nanoparticle albumin-bound paclitaxel in platinum-sensitive patients and platinum-resistant patients with ovarian,peritoneal,or fallopian tube canceral and bevacizumab with albumin-bound paclitaxel in patients with recurrent,platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma,which have shown the efficacy and tolerated adverse reactions. The study reported a phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer and point out that albumin-bound paclitaxel is a considering drug with little side effects. In short ,there is only a few study on albumin-bound paclitaxel in gynecologic oncology until now and we need more further study.

关 键 词：紫杉酚 宫颈肿瘤 卵巢肿瘤 子宫肿瘤 癌 肉瘤 

分 类 号：R737.3[医药卫生—肿瘤]